vs
Apellis Pharmaceuticals, Inc.（APLS）与Sprinklr, Inc.（CXM）财务数据对比。点击上方公司名可切换其他公司
Sprinklr, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$219.1M vs $199.9M），Sprinklr, Inc.净利率更高（1.3% vs -29.5%，领先30.8%），Sprinklr, Inc.同比增速更快（9.2% vs -5.9%），Sprinklr, Inc.自由现金流更多（$19.8M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Sprinklr是美国的一家SaaS企业，专注于客户体验管理（CXM）平台研发。其同名产品整合了社媒营销、社交广告、内容管理、团队协作、员工倡导、客户服务、社媒调研与监测等多类应用模块，为企业提供全链路的客户体验管理解决方案。
APLS vs CXM — 直观对比
营收规模更大
CXM
是对方的1.1倍
$199.9M
营收增速更快
CXM
高出15.1%
-5.9%
净利率更高
CXM
高出30.8%
-29.5%
自由现金流更多
CXM
多$34.1M
$-14.3M
两年增速更快
APLS
近两年复合增速
6.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $219.1M |
| 净利润 | $-59.0M | $2.9M |
| 毛利率 | — | 66.4% |
| 营业利润率 | -25.6% | 5.3% |
| 净利率 | -29.5% | 1.3% |
| 营收同比 | -5.9% | 9.2% |
| 净利润同比 | -62.2% | -72.2% |
| 每股收益（稀释后） | $-0.40 | $0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCXM
| Q4 25 | $199.9M | $219.1M | ||
| Q3 25 | $458.6M | $212.0M | ||
| Q2 25 | $178.5M | $205.5M | ||
| Q1 25 | $166.8M | $202.5M | ||
| Q4 24 | $212.5M | $200.7M | ||
| Q3 24 | $196.8M | $197.2M | ||
| Q2 24 | $199.7M | $196.0M | ||
| Q1 24 | $172.3M | $194.2M |
净利润APLSCXM
| Q4 25 | $-59.0M | $2.9M | ||
| Q3 25 | $215.7M | $12.6M | ||
| Q2 25 | $-42.2M | $-1.6M | ||
| Q1 25 | $-92.2M | $98.7M | ||
| Q4 24 | $-36.4M | $10.5M | ||
| Q3 24 | $-57.4M | $1.8M | ||
| Q2 24 | $-37.7M | $10.6M | ||
| Q1 24 | $-66.4M | $21.1M |
毛利率APLSCXM
| Q4 25 | — | 66.4% | ||
| Q3 25 | — | 68.2% | ||
| Q2 25 | — | 69.5% | ||
| Q1 25 | — | 71.0% | ||
| Q4 24 | — | 71.2% | ||
| Q3 24 | — | 72.6% | ||
| Q2 24 | — | 73.9% | ||
| Q1 24 | — | 75.5% |
营业利润率APLSCXM
| Q4 25 | -25.6% | 5.3% | ||
| Q3 25 | 48.7% | 7.7% | ||
| Q2 25 | -18.6% | -0.9% | ||
| Q1 25 | -50.0% | 5.2% | ||
| Q4 24 | -12.3% | 3.9% | ||
| Q3 24 | -24.0% | -0.0% | ||
| Q2 24 | -14.7% | 2.9% | ||
| Q1 24 | -36.0% | 9.5% |
净利率APLSCXM
| Q4 25 | -29.5% | 1.3% | ||
| Q3 25 | 47.0% | 5.9% | ||
| Q2 25 | -23.6% | -0.8% | ||
| Q1 25 | -55.3% | 48.7% | ||
| Q4 24 | -17.1% | 5.2% | ||
| Q3 24 | -29.2% | 0.9% | ||
| Q2 24 | -18.9% | 5.4% | ||
| Q1 24 | -38.5% | 10.9% |
每股收益（稀释后）APLSCXM
| Q4 25 | $-0.40 | $0.01 | ||
| Q3 25 | $1.67 | $0.05 | ||
| Q2 25 | $-0.33 | $-0.01 | ||
| Q1 25 | $-0.74 | $0.35 | ||
| Q4 24 | $-0.30 | $0.04 | ||
| Q3 24 | $-0.46 | $0.01 | ||
| Q2 24 | $-0.30 | $0.04 | ||
| Q1 24 | $-0.54 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $189.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $558.1M |
| 总资产 | $1.1B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCXM
| Q4 25 | $466.2M | $189.6M | ||
| Q3 25 | $479.2M | $125.4M | ||
| Q2 25 | $370.0M | $126.4M | ||
| Q1 25 | $358.4M | $145.3M | ||
| Q4 24 | $411.3M | $93.2M | ||
| Q3 24 | $396.9M | $119.1M | ||
| Q2 24 | $360.1M | $126.8M | ||
| Q1 24 | $325.9M | $164.0M |
总债务APLSCXM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCXM
| Q4 25 | $370.1M | $558.1M | ||
| Q3 25 | $401.2M | $543.4M | ||
| Q2 25 | $156.3M | $639.8M | ||
| Q1 25 | $164.2M | $612.1M | ||
| Q4 24 | $228.5M | $497.0M | ||
| Q3 24 | $237.1M | $469.0M | ||
| Q2 24 | $264.3M | $610.9M | ||
| Q1 24 | $266.7M | $679.7M |
总资产APLSCXM
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $970.3M | ||
| Q3 24 | $901.9M | $983.8M | ||
| Q2 24 | $904.5M | $1.1B | ||
| Q1 24 | $831.9M | $1.2B |
负债/权益比APLSCXM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $20.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $19.8M |
| 自由现金流率自由现金流/营收 | -7.1% | 9.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 6.87× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $142.3M |
8季度趋势，按日历期对齐
经营现金流APLSCXM
| Q4 25 | $-14.2M | $20.0M | ||
| Q3 25 | $108.5M | $34.8M | ||
| Q2 25 | $4.4M | $83.8M | ||
| Q1 25 | $-53.4M | $5.4M | ||
| Q4 24 | $19.4M | $9.2M | ||
| Q3 24 | $34.1M | $21.3M | ||
| Q2 24 | $-8.3M | $41.7M | ||
| Q1 24 | $-133.0M | $17.3M |
自由现金流APLSCXM
| Q4 25 | $-14.3M | $19.8M | ||
| Q3 25 | $108.3M | $34.4M | ||
| Q2 25 | $4.4M | $83.5M | ||
| Q1 25 | $-53.4M | $4.6M | ||
| Q4 24 | $19.3M | $8.2M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | $-8.4M | $39.2M | ||
| Q1 24 | $-133.3M | $15.2M |
自由现金流率APLSCXM
| Q4 25 | -7.1% | 9.0% | ||
| Q3 25 | 23.6% | 16.2% | ||
| Q2 25 | 2.5% | 40.6% | ||
| Q1 25 | -32.0% | 2.3% | ||
| Q4 24 | 9.1% | 4.1% | ||
| Q3 24 | — | 10.1% | ||
| Q2 24 | -4.2% | 20.0% | ||
| Q1 24 | -77.3% | 7.9% |
资本支出强度APLSCXM
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率APLSCXM
| Q4 25 | — | 6.87× | ||
| Q3 25 | 0.50× | 2.76× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 11.58× | ||
| Q2 24 | — | 3.92× | ||
| Q1 24 | — | 0.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CXM
| License And Service | $190.3M | 87% |
| Professional Services | $28.8M | 13% |
